MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET 2022-2028

Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Country Outlook | Forecast 2022-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

A Triton Market Research study shows that the market for immunoglobulin in the Middle East and Africa would develop with a CAGR of 5.19% in the forecast years 2022-2028.


Report scope can be customized per your requirements. Request For Customization

The countries studied in the market include:

•         United Arab Emirates

•         Saudi Arabia

•         South Africa

•         Turkey

•         Rest of Middle East & Africa

Factors such as strategic initiatives by top market players have significantly aided in boosting the demand for immunoglobulin in the Middle East and Africa. Moreover, the region witnessed innumerable product developments and launches, along with the growth of the pharmaceutical industry, R&D activities, increase in clinical trials, and significant investments in the biotechnology sector, which have contributed to the growth of the immunoglobulin market in the Middle East and Africa.

Turkey witnessed notable growth in the pharmaceutical sector, which is further expected to contribute to the growth of the immunoglobulin market. According to the Pharmaceuticals Manufacturers Association of Turkey, there has been a 19.9% growth in the pharma and medicinal products market. The vast shift in this market from $1.14 billion in 2015 to $3.17 billion in 2020 is expected to greatly aid the demand for immunoglobulin. Also, the pharma and medicinal products market reached 2.21 billion units in 2015 to 2.43 billion units in 2020, fueling the demand for immunoglobulin-based treatments to cater to different diseases and disorders. Thus, these factors are augmenting the market’s growth significantly.

The growth of the biotechnology sector in South Africa is fostering the immunoglobulin market. For instance, in 2021, BixBio, an African genomics startup, gained a large amount of funding from the Illumina Accelerator. The company is a biotechnology startup focusing on unlocking the potential of a wide array of genetic data while developing and expanding in precision medicine. Additionally, the contribution from Cipla to invest $80.81 million in a biotech plant to produce affordable cancer drugs is expected to promote the market’s growth.

Intravenous immunoglobulin is a blood product prepared from the serum of between 1,000 and 15,000 donors per batch. This type of treatment is commonly undertaken for patients with antibody deficiencies. The intravenous immunoglobulin treatment combines immunoglobulins donated by different people for treating different conditions. It is used for minimizing the effects of inflammatory conditions such as autoimmune diseases. Besides, it is also used to treat various conditions such as lupus, myositis, vasculitis, antiphospholipid syndrome, etc.

The studied report evaluates the market’s growth based on type, delivery mode, application, end-user, and sales channel. Here, the delivery mode segment comprises intravenous, subcutaneous, and intramuscular.

Key players in the immunoglobulin market include Octapharma AG, CSL Behring, Adma Biologics, Bio Products Laboratory, Takeda Pharmaceutical Company Limited, Grifols SA, LFB Group, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Pfizer Inc is a multinational pharmaceutical and biotechnology corporation. The company produces and develops vaccines and medicines for cardiology, oncology, endocrinology, immunology, and neurology. Moreover, the company has two business segments, Pfizer Biopharmaceuticals Group and Upjohn. The former deals in medicines, vaccines, and biosimilars to treat various diseases, while Upjohn offers products that treat non-communicable diseases. The company has a notable business presence across the Middle East and Africa.

 

Key deliverables of the report:

      Market CAGR during the forecasting years 2022-2028

      Detailed data highlighting key insights, industry components, and market strategies

    Comprehensive information and estimation of the immunoglobulin market revenue growth in the Middle East and Africa and its influence on the parent market

      In-depth study of forthcoming trends in consumer behavioral patterns

      A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model

  A wide-ranging study of factors that will challenge the Middle East and Africa immunoglobulin market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1. DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2. INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1. PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2. PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1. GROWTH IN THE GERIATRIC POPULATION

2.7.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1. HIGH COST OF THERAPY

2.8.2. HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1. INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2. GROWING CLINICAL TRIALS

3. MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4. MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5. MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10. OTHER APPLICATIONS

6. MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7. MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8. MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK

8.1. UNITED ARAB EMIRATES

8.2. SAUDI ARABIA

8.3. TURKEY

8.4. SOUTH AFRICA

8.5. REST OF MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11. PFIZER INC

9.12. SANQUIN PLASMA PRODUCTS BV

9.13. ADMA BIOLOGICS

9.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15. KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1. RESEARCH SCOPE & DELIVERABLES

10.2. SOURCES OF DATA

10.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: UNITED ARAB EMIRATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: SAUDI ARABIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: TURKEY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: SOUTH AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: REST OF MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;